Myeloid Therapeutics
45 employees on LinkedIn Β· 6 known investors
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis. The company's multi-immune platform enables off-the-shelf therapies with repeat dosing capability.
Also known as CREATE Β· CREATE Medicines Β· Myeloid Therapeutics, Inc.
Investors Β· 6
Also in the syndicate Β· 2
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BMay 2026
ARCH Venture Partners, Hatteras Venture Partners, Newpath Partners
Source β
Source: company announcements and press reports β follow each round's link for the claim.
Company profile
researched Aug 2026CREATE Medicines, previously named Myeloid Therapeutics, is a Cambridge, Massachusetts-based clinical-stage immunotherapy company developing chimeric antigen receptor (CAR) therapies that are generated inside the patient's body rather than by removing and engineering cells externally. Its platform combines proprietary mRNA-lipid nanoparticle (LNP) CAR constructs with targeted receptor/LNP delivery to program multiple immune lineages β T cells, NK cells and myeloid cells β in vivo. The company states that its in vivo CAR products have produced first-in-human evidence of mRNA uptake, CAR expression and tolerable repeat intravenous dosing, along with antigen presentation, cytokine and chemokine release, immune cell tumor infiltration, and induction of antitumor immune responses in the tumor microenvironment.
The disclosed pipeline spans oncology and autoimmune disease. Oncology programs listed as clinical include MT-302 (myeloid cells, TROP2, frontline gastroesophageal junction cancer), MT-303 (myeloid cells, GPC3, frontline hepatocellular carcinoma), MT-304 (NK and myeloid cells, HER2) and CRT-401 (T, NK and myeloid cells, HER2 x TROP2). Autoimmune programs listed as preclinical include CRT-402 (T cells, CD19) and CRT-403 (T cells, CD19 x BCMA, using a retrotransposon-based "RetroT" stability approach). Earlier, as Myeloid Therapeutics, the company advanced MT-101, an autologous CAR monocyte targeting CD5 derived from its ATAK platform, in a Phase 1/2 multi-dose ascending trial for T cell lymphoma; a glioblastoma candidate was later shelved to redirect funds.
Leadership includes cofounder and CEO Daniel Getts, Ph.D.; CFO/CBO Brett Kaplan, M.D.; CMO Matthew Maurer, M.D.; CSO Robert Hofmeister, Ph.D.; CTO Jerome Chal, Ph.D.; Chief People Officer Curtis Demick; Chief Financial Operations Officer Jason Walsh; and several clinical and translational vice presidents. Ron Philip, former CEO of Orbital Therapeutics, was recruited to chair the board in connection with the Series B.
Founding story
Myeloid Therapeutics launched publicly in January 2021 with more than $50 million in financing. Its scientific founders were Ronald Vale, Ph.D., a biochemist and cell biologist and executive director of HHMI's Janelia Research campus, and Siddhartha Mukherjee, M.D., D.Phil., a hematologist-oncologist and Pulitzer Prize-winning author. Daniel Getts, Ph.D., MBA β previously head of research at TCR2 through its IPO and a cofounder of Cour Pharmaceuticals Development Company β cofounded the company and serves as CEO. The ATAK cell platform was inspired by Vale and Mukherjee's view of the disease-fighting potential of myeloid cells.
Business model
Therapeutics developer funded by venture capital, advancing a proprietary pipeline of in vivo CAR product candidates through clinical development; it also enters research collaborations and in-licenses technology, as with the exclusive license agreement with Monash University.
Traction
Two therapies were reported in clinical testing as of May 2026 (in breast cancer and hepatocellular carcinoma), with the company's website listing four clinical-stage programs (MT-302, MT-303, MT-304, CRT-401) and two preclinical autoimmune programs. First-in-human data reportedly confirm mRNA uptake, CAR expression and tolerable repeat IV dosing. Cumulative disclosed financing includes over $50M at launch (2021), $73M (2023) and a $122M Series B (2026). Regulatory approval to initiate a first-in-human Phase 1/2 trial of CRT-402 was announced in July 2026.
Latest developments
In May 2026 the company announced a $122 million Series B from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and others, described as a step up in valuation and sufficient to fund early clinical trials, alongside the appointment of former Orbital Therapeutics CEO Ron Philip as board chair and the addition of Georg Schett, Margrit Wiesendanger and Christopher Jewell to its clinical and scientific advisory board. In July 2026 it announced regulatory approval to initiate a first-in-human Phase 1/2 trial of CRT-402 for autoimmune diseases and a strategic research collaboration and exclusive license agreement with Monash University.
βΈFull profile β market position, technology, go-to-market, geography, history, risks & controversies
Market position
Described by an investor in the Series B as the first fully in vivo CAR company with patient data; it competes within a cohort of in vivo CAR-T and next-generation cell therapy companies, several of which have been acquired by large pharmaceutical companies. Its named comparator in autoimmune in vivo CAR-T is Capstan Therapeutics.
The company positions its differentiation around multilineage in vivo programming across T, NK and myeloid cells, proprietary receptor and RNA engineering including retrotransposon-mediated stability, first-in-human clinical data confirming mechanism of action, and demonstrated tolerability with repeat dosing β enabling off-the-shelf therapies without patient-specific ex vivo manufacturing.
Technology
The core technology is in vivo immune cell programming using proprietary mRNA-LNP CAR constructs and targeted receptor/LNP delivery, enabling direct programming of T cells, NK cells and myeloid cells inside the body without ex vivo manufacturing. Additional elements include selective receptor design, RNA engineering with retrotransposon-mediated stability options ("RetroT") for RNA-based gene editing, and the earlier ATAK platform for CAR monocytes and primed monocytes, which used mRNA-encoded CARs delivered to a patient's own cells with a single-day manufacturing process and an eight-day vein-to-vein time.
Go-to-market
Clinical development of proprietary drug candidates through company-sponsored Phase 1/2 trials in solid tumors and, prospectively, autoimmune disease, supported by academic collaborations and licensing (Monash University) and a clinical/scientific advisory board of disease-area experts.
Patients with solid tumors (including gastroesophageal junction cancer, hepatocellular carcinoma, HER2- and TROP2-expressing tumors), hematologic malignancies, autoimmune diseases and fibrosis, reached through oncology and immunology clinical care settings.
Geography
Headquartered in Cambridge, Massachusetts, United States; research collaboration and exclusive license with Monash University (Australia).
History
The company launched in January 2021 from Cambridge, Massachusetts with over $50 million led by Newpath Partners, planning to enter the clinic in 2021 with programs in glioblastoma and T cell lymphoma. It ran a Phase 1/2 multi-dose ascending safety and tolerability trial of MT-101 (CD5-targeted autologous CAR monocyte) in T cell lymphoma. In May 2023 it closed a $73 million financing led by Hatteras Investment Partners to continue MT-101 development and accelerate MT-302 into Phase 1/2. The glioblastoma candidate was shelved around that period. The company rebranded from Myeloid Therapeutics to CREATE Medicines in the fall preceding a May 2026 report, expanded from oncology into autoimmune disease, and announced a $122 million Series B in May 2026. In 2026 it also announced a research collaboration and exclusive license with Monash University and clearance to start a first-in-human Phase 1/2 trial of in vivo CAR-T candidate CRT-402 in autoimmune diseases.
Risks & controversies
Sources note field-level headwinds: CAR-T therapies have faced scientific and commercial challenges despite early success in blood cancers, prompting some developers to pivot toward autoimmune indications. The company shelved an early glioblastoma candidate to reallocate funding, and it had not raised between 2023 and 2026 while peer companies were acquired. Comparative superiority claims by the CEO over competitor products are company statements rather than verified head-to-head data. No expanded access to MT-101 was offered pending further therapeutic data.
Compiled by commissioned research from 8 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 8
launches, deals, and filingsStrategic research collaboration and exclusive license agreement to expand the targeted in vivo CAR platform.
CREATE Medicines received approval to start a first-in-human Phase 1/2 clinical trial of in vivo CAR-T candidate CRT-402 for autoimmune diseases.
Series B from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and others, intended to fund early clinical trials; described by the CEO as a step up in valuation.
$122M source β
Appointment of Georg Schett, MD; Margrit Wiesendanger, MD, PhD; and Christopher Jewell, PhD to the clinical and scientific advisory board.
Former Orbital Therapeutics CEO Ron Philip joined to lead CREATE's board, following Orbital's acquisition by Bristol Myers Squibb for $1.5 billion.
The company rebranded in the fall preceding the May 2026 report and expanded from oncology into autoimmune disease research.
Proceeds to support clinical development of MT-101 in Phase 1/2 for T cell lymphoma and to accelerate MT-302, a TROP2-FcA mRNA-LNP product, into a Phase 1/2 study.
$73M source β
Company launched publicly in Cambridge, Mass., harnessing and reprogramming myeloid cells for cancer, with plans to enter the clinic in 2021 with programs in glioblastoma and T cell lymphoma.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
βΈResearch sources Β· 8
primary sources listed
- Myeloid Therapeuticsmyeloidtx.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Myeloid Therapeutics do?
- CREATE Medicines (formerly Myeloid Therapeutics) develops in vivo mRNA-LNP CAR therapies programming T, NK and myeloid cells.
- Who are Myeloid Therapeutics's investors?
- Myeloid Therapeutics's investors include ARCH Venture Partners, 8VC, Hatteras Venture Partners, Newpath Partners.